North America Theranostics Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)
North America Theranostics Market: by Type (Imaging Techniques, Therapeutic Agents, Biomarker Analysis, Companion Diagnostics, Radioisotopes, Nanoparticles), Application (Oncology, Cardiovascular Diseases, Neurological Disorders, Immunological Diseases, Infectious Diseases, Others), Distribution Channels (Hospitals, Diagnostic Centers, Research Laboratories, Retail Pharmacies, Online Pharmacies, Others), Technology (PCR, In Situ Hybridization, Immunohistochemistry, Sequencing, Microarrays, Others), Organization Size (Small, Medium, Large) and By North America Historical & Forecast Period (2020-2035) Comprehensive Study 2025
Last Updated: 31-07-2025 | Format: PDF | Report ID:20498 | Author: Lily
North America Theranostics Market Size, Share and Forecast (2025-2035)
The North America Theranostics Market leverages advanced diagnostic and therapeutic approaches for personalized medicine, combining targeted therapies and diagnostics for improved patient outcomes. Key components encompass imaging techniques, therapeutic agents, biomarker analysis, companion diagnostics, radioisotopes, and innovative nanoparticles. The market has expanded rapidly due to the increasing incidence of chronic diseases, the shift toward precision medicine, and robust healthcare infrastructure across the region. Demand for personalized therapies in oncology and cardiovascular segments is driving major innovations. Latest advancements in molecular diagnostics, regulatory approvals, and collaborations between industry leaders and research institutes further accelerate market adoption. However, the market faces hurdles such as regulatory complexities, high development costs, and reimbursement challenges. The future outlook remains optimistic, with continuous investments in R&D and the integration of AI-driven technologies poised to transform theranostic solutions.
Latest Market Dynamics
Key Drivers
Rising prevalence of cancer and chronic diseases across the US and Canada has propelled demand for personalized treatment solutions. For instance, in 2025, Siemens Healthineers advanced its PET/CT imaging platforms to support integration with theranostic radiopharmaceuticals, enhancing both diagnosis and treatment monitoring.
Growth in genomics and molecular diagnostics, led by companies like Thermo Fisher Scientific, enables precise companion diagnostics and tailored therapies. In May 2025, Thermo Fisher launched expanded panels for liquid biopsy, allowing advanced molecular profiling in oncology.
Key Trends
Increasing adoption of radiotheranostics in targeted oncology treatments, highlighted by GE Healthcare's partnership announced in early 2025 with pharmaceutical companies to commercialize next-generation radioisotope therapies.
Expansion of partnerships among biotech, pharma, and digital health companies, as seen with Abbott Laboratories' strategic collaboration in June 2025 for AI-powered diagnostic-theranostic platforms targeting cardiovascular diseases.
Key Opportunities
Integration of AI and machine learning with theranostic workflows, exemplified by Roche’s June 2025 acquisition of a leading AI diagnostics start-up to accelerate personalized oncology care.
Expansion into non-oncology applications such as neurodegenerative and cardiovascular diseases, with Bracco Diagnostics Inc. releasing innovative nanotechnology-based agents in July 2025.
Key Challenges
Regulatory hurdles facing approval of combined diagnostic and therapeutic agents, as highlighted by Bayer AG's ongoing FDA negotiations in August 2025 for novel radioisotope therapies.
High R&D costs and complexity in clinical trials create financial pressures for mid-sized players, evidenced by Qiagen’s halted development program for a neurotheranostic panel in July 2025.
Key Restraints
Uncertainties in reimbursement policies for theranostic procedures, impacting commercialization, as stated by Cardinal Health in their June 2025 earnings report.
Limited awareness among clinicians on integrated theranostic approaches, despite educational investments from Merck & Co., Inc. announced in July 2025.
North America Theranostics Market Share (%) by Type, 2025
In 2025, imaging techniques hold the largest share (32%) of the North America Theranostics Market by type, followed by therapeutic agents (25%) and biomarker analysis (16%). Advanced imaging continues to advance precision and real-time treatment adjustments. The growth of therapeutic agents is fueled by rising acceptance of radioisotopes and nanoparticles for personalized interventions, offering higher efficacy and minimized side effects. The segment for companion diagnostics and biomarker analysis is expanding as these technologies enable personalized stratification and monitoring. Investments in nanotechnology and next-generation radioisotopes are expected to further augment their respective shares as clinical adoption widens. Regulatory approvals for hybrid modalities and cross-segment collaboration are anticipated to drive overall market growth through 2035.
North America Theranostics Market Share (%) by Applications, 2025
Oncology dominates the North America Theranostics Market by application in 2025, holding 58% share, underpinned by increasing cancer prevalence and robust clinical research investments. Cardiovascular diseases account for 14%, leveraging recent advances in molecular diagnostics and targeted therapy. Neurological disorders (11%) are also gaining traction as theranostic products for Alzheimer’s and Parkinson’s enter late-stage development. Immunological and infectious diseases represent emerging segments at 9% and 6% respectively, with others encompassing a minor share. Overall, oncology remains at the forefront due to its established use cases and reimbursement models, while expansion into other indications is poised to accelerate as new biomarkers and companion diagnostics receive regulatory endorsement.
North America Theranostics Market Revenue (USD Million), 2020-2035
The North America Theranostics Market revenue displayed strong growth from 2020 to 2025, rising from 1,250 million USD to 2,020 million USD, driven by escalating investments in personalized medicine and new product launches. Projections through 2035 forecast sustained upward momentum, with market value expected to surpass 5,560 million USD by the end of the period. This robust trajectory is attributable to continuous R&D, partnerships among key players, and increasing clinical adoption of comprehensive theranostic platforms in both oncology and non-oncology domains. The market’s resilience against economic volatility and expanding reimbursement coverage further solidify its long-term potential.
North America Theranostics Market YOY Growth (%), 2020-2035
Between 2020 and 2025, the North America Theranostics Market’s year-on-year (YOY) growth remained robust, averaging 8.5% due to ongoing innovation and favorable healthcare infrastructure. The post-2025 period shows annual growth moderating slightly, yet sustaining a healthy pace of 7-10%, reflecting a maturing but dynamic market. YOY growth peaks around 2034-2035, approaching 13%, linked to the commercial rollout of next-generation theranostic agents and expansion into new disease areas. Expansion of insurance coverage and faster regulatory approvals are projected to underpin continued momentum.
North America Theranostics Market Share (%) by Region, 2025
The United States leads with a commanding 76% share of the North America Theranostics Market in 2025, owing to advanced research ecosystems and early adoption of innovative diagnostics. Canada accounts for 14% as it expands research collaborations and clinical deployments, while Mexico represents 10% with emerging adoption focused on urban healthcare centers. The US dominance reflects strong investments, presence of top industry players, and robust regulatory support, while opportunities in Canada and Mexico are rising as infrastructure matures and awareness increases.
North America Theranostics Market Players Share (%), 2025
Major multinational players dominate the North America Theranostics Market in 2025, with GE Healthcare holding 16%, Siemens Healthineers 14%, and Thermo Fisher Scientific at 13%. Other notable companies include Abbott Laboratories, Roche, Bayer, Cardinal Health, and Bracco Diagnostics, sharing the remaining market pool. Competition is driven by technological innovation, product diversification, and strategic collaborations, enabling leaders to strengthen their market position. Mergers, acquisitions, and continuous product launches drive market share polarization among the leading players.
North America Theranostics Market Buyers Share (%), 2025
Hospitals represent the largest buyer group for theranostic solutions in North America at 43% market share in 2025, driven by the concentration of advanced diagnostics infrastructure. Diagnostic centers capture 22%, followed by research laboratories (16%), retail pharmacies (10%), online pharmacies (6%), and others (3%). Hospitals' dominance is underpinned by comprehensive service offerings and investments in new technologies, while diagnostic and research laboratories benefit from growing clinical trial and personalized medicine activity.
Study Coverage
Metrics
Details
Years
2020-2035
Base Year
2025
Market Size
2020
Regions
US, Canada, Mexico
Segments
Type, Application, Technology, Distribution Channels, Organization Size
June 2024: Thermo Fisher Scientific launched a next-gen liquid biopsy companion diagnostic panel targeting advanced solid tumors.
July 2024: Roche acquired a US-based AI diagnostics start-up to enhance its oncology theranostics pipeline.
August 2024: Bayer AG initiated FDA approval discussions for a new radiotheranostic for metastatic prostate cancer.
July 2024: Bracco Diagnostics Inc. received Health Canada clearance for a nanoparticle-based neuroimaging agent.
June 2024: Abbott Laboratories partnered with a digital health company to introduce an AI-powered cardiovascular diagnostic-theranostic solution.
Frequently Asked Questions
About the Author
Lily
Senior Market Research Analyst
Lily is a Senior Market Research Analyst specializing in market research, industry analysis, and business consulting across Healthcare. Lily brings a commercially grounded perspective to sectors shaped by changing demand, innovation, and competitive dynamics, helping turn complex market trends into clear strategic insights for business decision-makers. With 10+ years of experience across research, analytics, and strategic advisory roles, Lily has helped organizations translate data into actionable growth strategies.
